NEKTAR THERAPEUTICS (NKTR) INVESTOR ALERT Investors With Large Losses in Nektar Therapeutics Should Contact Bernstein Liebhard LLP To Discuss Their Rights
GlobeNewswire | Bernstein Liebhard LLP
Today at 9:58pm UTC
NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, inclusive.
If you wish to serve as lead plaintiff for the Class, you must file papers by May 5, 2026. A lead plaintiff is a representative party acting on other class members’ behalf in directing the litigation. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
About The Lawsuit:
According to the lawsuit, Defendants made misrepresentations concerning the Phase 2b trial for REZOLVE-AA.
About Bernstein Liebhard:
Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of class actions, the Firm has been named to The National Law Journal’s “Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for sixteen consecutive years.
Stuff the Bus Foundation founder Tony Rose (left), hands Foundation President Kyle Wolz a box of donated school supplies Saturday during the annual Stuff the Bus event at Crossroads Express in 2022.
